Molecular and cellular bases of lipodystrophy syndromes
Our findings underscore the possibility for wider applications for these medications but also highlight important risks that should be carefully monitored in people taking these drugs. Nature Medicine: Mapping the effectiveness and risks of GLP-1 receptor agonists
Ongoing Support: Our team is with you every step of the way, offering regular check-ins, adjustments to your plan, and expert advice to ensure your success
The published human evidence does not define an optimal cycle length for Ipamorelin, so the ranges below are documented conventions, not established facts
Table of Contents Why this conversation matters Guest snapshot Peptides 101 Safe, practical peptide picks Regulatory and safety landscape NAD, exosomes, and their place GLP1 medications and microdosing Practical care pathways Gut health as the foundation Hormone replacement therapy (HRT) for midlife women Exercise, resistance training, and practical tools Supplements and small wins Finding a clinician: what to look for Common myths and straightforward truths Patient stories and the human side Practical checklist for someone considering peptides or GLP1s Resources FAQ Final practical notes from our clinical experience Where to learn more Closing practical tip Why this conversation matters We are living through a moment when new metabolic and regenerative tools are more accessible than ever